Canavan disease …

Neurogenetic Disorders

Updated 04.14.2024
Released 06.20.1994
Expires For CME 04.14.2027

Canavan disease

Authors: Alex Sunshine MD PhD, Margie A Ream MD PhD

See Contributor Disclosures

Editor: Erika Fullwood Augustine MD MS

Canavan disease

In This Article

Quick Link

Introduction

Overview

Canavan disease is a leukodystrophy that causes progressive degeneration, resulting in a spongy deterioration of the brain. The disease is due to mutations in ASPA (OMIM *608034), which encodes aspartoacylase, an enzyme that catalyzes the conversion of N-acetylaspartic acid to aspartate and acetate. In this article, the authors present the history of Canavan disease, current understanding of the pathophysiology, diagnostic work-up, and new therapies that are being developed to treat this rare and devastating condition.

Key points

	• Aspartoacylase deficiency in Canavan disease leads to spongy degeneration of the white matter.
	• Aspartoacylase deficiency leads to increased N-acetylaspartic acid in blood, CSF, brain tissue, and urine.
	• Diagnosis of Canavan disease can be achieved through imaging, biochemistry, and molecular assay.
	• Brain magnetic resonance imaging (MRI) findings in patients with Canavan disease show early involvement of the subcortical U-fibers. Magnetic resonance spectroscopy (MRS) shows an elevated N-acetylaspartate peak.
	• Carrier screening is recommended for people of Ashkenazi Jewish descent.
	• New therapies, including new gene therapies, are currently being investigated for Canavan disease.

Historical note and terminology

Canavan disease, or Canavan-Van Bogaert-Bertrand disease, was first described in 1931 by Myrtelle Canavan (14). The description by Canavan subsequently dominated the American medical literature when spongy degeneration of the brain came to be recognized as a specific entity. A detailed report of three Jewish children with spongy degeneration of the brain was published in 1949 and is widely quoted in the European literature (65). Since then, numerous cases of Canavan disease have been reported, and Canavan disease has been shown to have a higher prevalence in the Ashkenazi Jewish population (06).

The enzyme responsible for Canavan disease, aspartoacylase, was identified in 1988 (46). The gene was cloned in 1993 (33). These advancements enabled identification of pathogenic variants in patients, family members, and at-risk populations (33; 44). Additionally, the understanding that deficiency of aspartoacylase leads to increased concentration of N-acetylaspartic acid in CSF, serum, and urine has enabled the diagnosis of Canavan disease through biochemical methods.

Clinical manifestations

Presentation and course

• Two subtypes of Canavan disease have been described based on age of onset: infantile and juvenile.

Infantile form. The infantile form of Canavan disease is the more common form and is characterized by the triad of developmental delay, hypotonia, and acquired macrocephaly. Babies born with Canavan disease do not have distinctive clinical features in their first few months of life. However, delayed development is often first noted at about 3 months of age. Likewise, in early infancy, the head circumference and brain may not be remarkably increased and may be at the upper limit of normal in some cases. However, in the majority of cases, head circumference and brain size will dramatically increase after the age of 6 months and is usually above the 90th percentile by 1 year. In these infants, MRI often shows diffuse cerebral white matter degeneration with early involvement of the subcortical U-fibers. T2 hyperintensities in the cerebellum, periventricular white matter, basal ganglia, thalami, and brainstem can also be seen (69; 59). As the infant grows older, developmental milestones are not achieved. This includes developmental delays in gross motor, fine motor, and language development. As the disease progresses, developmental regression occurs. Patients with Canavan disease also develop nystagmus, poor visual tracking, pronounced startle reflex, feeding difficulties, sleep disturbances, and epilepsy (12). Although possible in the first year of life, seizures and optic atrophy usually develop in the second year of life (44; 12).

In order to better characterize the phenotype of Canavan disease, a symptom scoring system, known as the Canavan disease severity score, has been proposed (12). The system is 22 points and is based on 11 clinical features, including epileptic seizures, truncal hypotonia, appendicular hypertonia/spasticity, macrocephaly, difficulties with feeding, difficulties with language, the lack of a responsive social smile, difficulties with visual track, difficulties with head control, difficulty with reaching for objects, and difficulties in sitting without support. In the new scoring system, a 0 is assigned if no deficit is present, a 1 is assigned if there is a mild deficit, and a 2 is assigned if there is a constant or pronounced deficit. The scoring system can help keep track of disease progression and may be useful to determine the efficacy of new therapies that are developed.

Juvenile form. In contrast to the infantile form of Canavan disease, the juvenile form tends to have a much milder phenotype (48). In the juvenile form of Canavan disease, macrocephaly and spongiform changes on MRI may not develop. However, juvenile-onset cases with macrocephaly, seizures, and retinitis pigmentosa have been reported (62; 63; 08). Patients with the juvenile form of Canavan disease tend to present in early childhood as opposed to infancy and tend to have mild, if any, developmental delays without regression (43). MRI abnormalities that have been seen in the juvenile cases have included mild T2-weighted and FLAIR hyperintensity changes in the arcuate fibers, striatum, dentate nuclei, and the pons (55; 13).

Prognosis and complications

The prognosis for infantile Canavan disease is poor but improving. Previously, most children with the infantile form of Canavan disease died by the age of 3 years. A new natural history study revealed that 73% of patients are now surviving at 10-year follow-up (12). With age, contractures and spasticity develop and resemble findings that occur in cerebral palsy (45). Due to problems with feeding, including dysphagia and gastroesophageal reflux, as well as poor weight gain, some children with Canavan disease require nasogastric feeding or a gastrostomy tube. In contrast to infantile Canavan disease, children with the juvenile form can have a typical life span and more limited symptoms, including mild developmental delay, optic atrophy, or retinitis pigmentosa.

Clinical vignette

A white, male infant was born at term with an unremarkable pregnancy and delivery. Birth length, weight, and head circumference were all at the 50th percentile. The neonatal exam was normal. At 3 months of age, he was noted to be irritable with poor sleep, and he gagged during feedings. A diagnosis of gastroesophageal reflux was suspected, and he was treated with cisapride. At 6 months of age, he continued to be irritable, and delayed milestones were noted. He could raise his head when prone but could not maintain head control when in an upright position. There was marked hypotonia noted on examination, and he was referred for a neurologic consultation. Because of developmental delays, hypotonia, and an increase of head circumference to the 90th percentile, MRI of the brain was performed. The MRI showed delayed maturation of the white matter. Perinatal injury was suggested as a possible etiology. At 14 months of age, he still could not sit, stand, or support his head. At that time, a second brain MRI showed widespread white matter T2 hyperintensity that involved U-fibers. Urine studies revealed an elevated N-acetylaspartic acid concentration of 1650 µmol/mmol creatinine (normal less than 40 µmol/mmol creatinine), and the diagnosis of Canavan disease was made.

Biological basis

• Aspartoacylase deficiency in Canavan disease leads to accumulation of N-acetylaspartic acid and spongy degeneration of the white matter, although the specific mechanism for this is not fully understood.

Etiology and pathogenesis

Canavan disease is an autosomal recessive disorder due to aspartoacylase deficiency that results from pathogenic variants affecting the aspartoacylase gene (ASPA) located on chromosome 17 (46). Histologically, it is characterized by spongiform vacuolization, which is seen throughout the subcortical white matter in both the cerebrum and cerebellum. The spongiform vacuolization seen in histological sections is due to vacuole formation within individual astrocytes and between myelin lamellae (02; 01).

Pathogenic variants in ASPA in patients with Canavan disease cause decreased aspartoacylase activity. Disease severity is inversely proportional to the amount of residual enzyme activity. The most severe forms of Canavan disease have less than 1% of normal enzyme activity (72; 48).

Although the enzyme defect is known, much about the pathogenesis is still unclear. Mouse models of the disease have provided evidence that the pathogenesis of Canavan disease involves steps in synthesis, transport, and breakdown of N-acetylaspartic acid. N-acetylaspartic acid is the second most common amino acid in the brain and is made by the enzyme aspartate N-acetyltransferase (ANAT) in humans, which is encoded by the N-acetyltransferase-8 like (NAT8l) gene. After its synthesis, primarily in neurons, N-acetylaspartic acid released in the extracellular space before it is taken up by glial cells (including astrocytes and oligodendrocytes) or taken up through the glymphatic circulation back to the general circulation. In oligodendrocytes, N-acetylaspartic acid is broken down into L-aspartate and acetate by aspartoacylase. In astrocytes, N-acetylaspartic acid is then transported to endothelial cells/the blood stream or converted to N-acetylaspartylglutamate. Once in the blood stream, NAA can be excreted via the kidneys or reabsorbed via the dicarboxylic transported NaDC3. There are three leading hypotheses regarding the pathophysiology of Canavan disease: the acyl-myelin theory, the N-acetylaspartic acid toxicity theory, and the molecular water pump theory.

The acyl-myelin theory is centered on the idea that oligodendrocytes deficient in aspartoacylase are unable to form myelin. This deficiency prevents oligodendrocytes from forming acetate. The inability to derive acetate from N-acetylaspartic acid interferes with myelin production through two mechanisms. First, acetate serves as a precursor molecule for myelin lipid production, and second, acetyl-CoA derived from acetate is a substrate for ATP formation through the citric acid cycle (52; 41). It has also been found that the acetate generated from the hydrolysis of N-acetylaspartic acid is used in other ways, such as epigenetic regulation of gene expression, including acetylation of histones (54). Acetate deficiency likely causes myelin pathology through a combination of these mechanisms.

The N-acetylaspartic acid toxicity theory is based on the idea that elevated levels of N-acetylaspartic acid are toxic to astrocytes and oligodendrocytes. According to this theory of pathogenesis, astrocytes take up N-acetylaspartic acid through SLC13A3 before transporting it to oligodendrocytes. Elevated N-acetylaspartic acid in both astrocytes and oligodendrocytes can lead to oxidative stress and vacuolization (50). N-acetylaspartic acid also binds to and activates NMDA receptors (36). It is speculated that the activation of NMDA receptors by N-acetylaspartic acid could lead to the seizures that are seen in Canavan disease (41). Previous studies have also shown that aspartoacylase-deficient mice can be rescued from developing spongiform degeneration by homozygous knockout of Nat8l (the enzyme that forms N-acetylaspartic acid). Lastly, in cultured stomach cells, N-acetylaspartic acid can activate NF kappa B activity and MAP kinases, which leads to the expression of inducible nitric oxide synthase and cell death (60; 61).

The molecular water pump theory is based on the idea that N-acetylaspartic acid serves as an osmolyte in the brain. In a study in which the dorsal lateral striatum of rats was exposed to increasing hypoosmotic media, the concentration of N-acetylaspartic acid increased in the extracellular matrix, implying that N-acetylaspartic acid may be protective against hyposmolar damage at physiologic levels (64). The osmotic activity of N-acetylaspartic acid may require a delicate balance, such that excess intracellular N-acetylaspartic acid could lead to vacuole formation within cells such as astrocytes, and excess extracellular N-acetylaspartic acid between oligodendrocyte lamellae could lead to splitting of the myelin lamellae and extracellular vacuolization.

None of these theories are mutually exclusive, and they may all contribute to the pathology seen in Canavan disease.

Epidemiology

• Canavan disease occurs in people of all ethnicities; however, it is most prevalent among those of Ashkenazi Jewish descent.

Canavan disease is panethnic. It is most prevalent among Ashkenazi Jews of Eastern European descent; however, there is increasing recognition that it may be more prevalent in other ethnic groups than previously thought (12). In the Ashkenazi Jewish population, two specific mutations predominate. A missense mutation on codon 285 with substitution of glutamic acid to alanine (p.Glu285Ala) accounts for 84% of pathogenic variants identified in a large number of Jewish patients, and a nonsense mutation, tyrosine to termination, on codon 231 (p.Tyr231X) for 13.4% (42). Together these two variants account for over 97% of the alleles in Jewish Canavan patients.

Study of blood specimens from over 5000 healthy Ashkenazi Jewish people indicated that one out of 37.7 were carriers for the two common mutations (47). Carrier frequency for these two mutations in a Jewish population was 1:82 in Israel and 1:57 in Canada (21; 20). These frequencies depend on the population tested and their countries of origin. Ashkenazi Jewish people from Ukraine or Lithuania are probably the main founders of the Jewish mutations.

In non-Jewish patients, the mutations are more varied. The most common Canavan mutation in non-Jewish patients is in codon 305, a missense mutation that substitutes alanine with glutamic acid (p.Ala305Glu) (34; 45). Molecular characterization of Canavan disease in the Indian subcontinent has revealed additional variants (p.Ile243Ser, p.Leu301Pro, and p.Gly176Ser) and two known mutations that were subsequently used for prenatal diagnosis (10; 37). Patients with juvenile or mild forms of Canavan disease are often compound heterozygotes, with a mild mutation on one allele and a severe mutation on the other allele. Mild mutations include p.Tyr288Cys, p.Phe295Ser, p.Lys213Glu, p.Arg305Glu, and p.Arg71His (62; 63; 69; 31).

Diagnostic workup

	• Imaging of the brain is the first step in the diagnostic workup.
	• Elevation of N-acetylaspartic acid in blood, urine, CSF, or on MRS is a specific indicator of Canavan disease.

Imaging of the brain, via cranial ultrasound, computed tomography (CT), or MRI with spectroscopy of the brain, is useful in the diagnostic work-up of Canavan disease. Cranial ultrasound of patients with Canavan disease can reveal pial hyperechogenicity, cortical gray matter hypoechogenicity, subcortical white matter hyperechogenicity (sparing the corpus callosum) with small isolated cystic changes, and brainstem hyperechogenicity (18; 56). CT will often reveal diffuse white matter degeneration (57). MRI is the preferred modality for visualizing white matter abnormalities and can reveal diffuse white matter degeneration with early involvement of the subcortical U-fibers and variable T2 hyperintensity in the cerebellum, basal ganglia, thalami, and brainstem (69; 59). Patients with mild variants of Canavan disease have mild T2-weighted and FLAIR hyperintensity changes in the arcuate fibers, striatum, dentate nuclei, and pons (55; 13). Although rare, a cribriform appearance of the brain on MRI due to numerous cystic lesions has also been reported in patients with Canavan disease (09). MRS shows an increased N-acetylaspartic acid peak (27; 68), even if serum and urine N-acetylaspartic acid are normal (32). It is important to note that the initial ultrasound, CT, or MRI may be interpreted as normal early in life. As a result, follow-up imaging is indicated if there remains a suspicion for metabolic brain disease (11).

Although imaging is helpful, biochemical and molecular tests are more specific than MRI findings and are used to diagnose Canavan disease. Patients with severe Canavan disease typically have highly elevated levels of urine N-acetylaspartic acid (1440 + 873 mmol/mmol creatinine vs. normal 23 +16 mmol/mmol creatinine), although normal or slightly elevated levels can be found in some patients. In those cases, diagnosis is made through other methods, such as molecular testing (28). Molecular testing to obtain ASPA genotype can be accomplished through single gene testing, genetic panels, or whole exome or genome sequencing. Enzyme activity can be measured in cultured skin fibroblasts but is not necessary if N-acetylaspartic acid is elevated in blood, urine, or CSF or if a pathogenic APSA mutation is identified.

Once a biochemical diagnosis of Canavan disease is reached, DNA mutation analysis of the ASPA gene should be performed on the proband as well as on family members for counseling and preventive measures (44). Prenatal and preimplantation testing is available (70).

Management

	• Management of Canavan disease is symptomatic.
	• Advances in the understanding of the pathophysiologic mechanisms behind Canavan disease will aid in the discovery of new therapies.
	• Clinical trials of promising therapies are underway.

Outcomes

There are currently no cures for Canavan disease, and therapy focuses on mitigating complications. For instance, physical therapy may help prevent contractures, and seizures are managed with antiseizure medication. In addition, special care is needed to avoid aspiration with feedings. Nasogastric or gastrostomy feeding is often necessary. In addition to the aforementioned recommendations, reviews have been published to help guide clinicians in the treatment of patients with leukodystrophies (03; 35). Once a diagnosis of Canavan disease is made, patients should receive recurrent neurologic evaluations along with developmental assessments. Due to optic atrophy and associated retinitis pigmentosa, recurrent ophthalmologic exams should also be performed. In addition, carriers should have access to genetic counseling prior to planning a pregnancy.

Therapies under investigation. Significant efforts have been made to find disease-modifying therapies as our understanding of the pathophysiology of Canavan disease has advanced. This includes the study of nutritional supplements, lithium, small molecules, enzyme replacement therapy, and cell-based therapies as well as the development of gene therapy products. Multiple knockout mouse models for Canavan disease have been created, which are useful in the preclinical evaluation of potential therapies (41).

Nutritional supplements and lithium. In the past, a clinical trial of glycerol triacetate (inspired by the acyl-myelin hypothesis) in Canavan disease did not demonstrate clinical efficacy (58). Resveratrol is thought to have therapeutic potential for Canavan disease due to its ability to upregulate the ASPA gene, which is mutated in Canavan disease (16). In addition, resveratrol, which generally plays a prominent role in metabolism and in mitochondrial function, restores fatty acid beta-oxidation capacities in the Canavan patient–derived cell line, GM04268.

In addition to resveratrol, Francis and colleagues found that in a mouse model of Canavan disease, dietary triheptanoin promoted oligodendrocyte survival, increased myelination, decreased vacuolization, and improved motor activity in the mice that were given triheptanoin compared to control mice (23). Lipoic acid may act as an antioxidant and prevent damage from N-acetylaspartic acid (50; 51). Lastly, lithium citrate given to six patients for 60 days was associated with decreased N-acetylaspartic acid in the basal ganglia, mild improvement in myelination in frontal white matter, increased myelin density in the corpus callosum, and increased levels of alertness (05).

Small molecules. Small molecules that inhibit either the production of N-acetylaspartic acid or aspartate N-acetyltransferase (ANAT)–mediated production of N-acetylaspartic acid are being investigated. A large-scale screening of 10,000 compounds identified two potential inhibitors (compounds 2516-4695 and V002-2064) (49). In addition to ANAT inhibitors, inhibiting N-acetylaspartic acid transport through NaDC3 (encoded by SLC13A3) is also being proposed as a therapeutic mechanism. Wang and colleagues showed that mice that had both the aspartylacylase and the SLC13A3 genes knocked down had normalized N-acetylaspartic acid levels in the CSF, developed less vacuolization in the brain, and had improved motor performance (66). However, it should be noted that at least two patients with SLC13A3 variants developed leukoencephalopathy after febrile illnesses (17). Topiramate administration also has been found to be associated with decreased head growth velocity in two patients. The exact mechanism behind this is not known. It is speculated that topiramate could decreased the accumulation of water in the brain secondary to inhibiting carbonic anhydrase. It is worth noting that acetazolamide (another carbonic anhydrase inhibitor) has not been shown to decrease head growth velocity, indicating that topiramate impacts growth velocity through other mechanisms (67).

Enzyme replacement. Enzyme replacement therapy is a therapeutic option that has been used in other disorders, such as Gaucher disease, and strategies to create an enzyme replacement therapy for Canavan disease are underway (40). Aspartoacylase injected into knockout mice with Canavan disease leads to increased aspartoacylase activity in the mouse brain (71; 53). Despite the success in mice, efficacy of such treatment in Canavan disease has yet to be demonstrated in clinical trials.

Cell-based therapies. Cell-based therapy development for Canavan disease is currently underway in preclinical stages. Two studies demonstrated how using gene-editing techniques or lentiviral transduction of patient-derived induced pluripotent stem cells with wildtype ASPA, transformed into induced oligodendrocyte precursor cells (iOPCs) or induced neuron precursor cells (iNPCs) that express aspartoacylase, can be used to a mouse model of Canavan disease (22; 15). When transplanted into a mouse model of Canavan disease, these transformed cells resulted in significant improvement in motor activity and decreased vacuolization and N-acetylaspartic acid levels. Such patient-specific cell-based therapies do not trigger rejection as allogenically derived stem cells can; however, they are costly and carry a risk of malignant transformation.

Gene therapy. Gene therapy using viral vectors or anti-sense oligonucleotides (ASOs) for the treatment of Canavan disease is under investigation in both mouse models and humans. In mice, spongiform degeneration can be suppressed by the addition of acetyl-aspartase or the deletion of the enzyme that creates N-acetylaspartic acid (Nat8l) (38; 39; 30; 07; 29; 24). AAV gene therapy simultaneously employing both approaches reversed many pathological features (including demyelination and astrogliosis) in a late-stage Canavan disease mouse model (25).

At least four different gene therapies for the treatment of Canavan disease in humans have been developed. In the first study, the aspartoacylase gene was transferred to two children with Canavan disease using liposomes (38). Subsequently, gene therapy of Canavan disease was achieved using adeno-associated virus 2 (AAV2) as a vector for aspartoacylase in a phase 1 study, which did not identify substantial toxicity (30). The 5-year follow-up showed long-term safety, with some decrease in the elevation of N-acetylaspartic acid in brain, improvement in seizure frequency, and stabilization of overall clinical status (39).

In addition to these previous studies, one open-label phase 1/phase 2 clinical trial is underway (NCT04833907). In this trial, the ASPA gene is being delivered intracerebroventricularly with AAV/Olig001, with the goal of aspartoacylase expression in oligodendrocytes. In the second trial (NCT04998396), the gene for aspartoacylase is being delivered intravenously with an AAV9 vector to facilitate aspartoacylase expression in both neuronal and non-neuronal cell types. In another trial, (NCT04833907, enrollment complete), the ASPA gene was delivered intracerebroventricularly with AAV/Olig001, with the goal of aspartoacylase expression in oligodendrocytes. Results from this study are pending.

References

01: Adachi M, Schneck L, Cara J, Volk BW. Spongy degeneration of the central nervous system (van Bogaert and Bertrand type; Canavan's disease). A review. Hum Pathol 1973;4(3):331-47. PMID 4593851
02: Adachi M, Torii J, Schneck L, Volk BW. Electron microscopic and enzyme histochemical studies of the cerebellum in spongy degeneration (van Bogaert and Bertrans type). Acta Neuropathol 1972;20(1):22-31. PMID 4112017
03: Adang LA, Sherbini O, Ball L, et al. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Mol Genet Metab 2017;122(1-2):18-32. PMID 28863857
04: Anonymous. Committee opinion no. 691: carrier screening for genetic conditions. Obstet Gynecol 2017;129(3):e41-55. PMID 28225426
05: Assadi M, Janson C, Wang DJ, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan Disease. Eur J Paediatr Neurol 2010;14:354-9. PMID 20034825
06: Banker BQ, Victor H. Spongy degeneration of infancy. In: Goodman RM, Motulsky AG, editors. Genetic diseases among Ashkenazi Jews. New York: Raven, 1979:201-17.
07: Bannerman P, Guo F, Chechneva O, et al. Brain Nat8l knockdown suppresses spongiform leukodystrophy in an aspartoacylase-deficient Canavan disease mouse model. Mol Ther 2018;26(3):793-800. PMID 29456021
08: Benson MD, Plemel DJA, Freund PR, et al. Severe retinal degeneration in a patient with Canavan disease. Ophthalmic Genet 2021;42(1):75-8. PMID 32975148
09: Bhat MD, Manjunath N, Kumari R, et al. Cribriform appearance of white matter in Canavan disease associated with novel mutations of ASPA gene. J Pediatr Genet 2022;11(4): 267-71. PMID 36267868
10: Bijarnia S, Kohli S, Puri RD, et al. Molecular characterisation and prenatal diagnosis of Asparto-acylase deficiency (Canavan disease) –report of two novel and two known mutations from the Indian subcontinent. Indian J Pediatr 2013;80(1):26-31. PMID 22878930
11: Biswas A, Malhotra M, Mankad K, et al. Clinico-radiological phenotyping and diagnostic pathways in childhood neurometabolic disorders-a practical introductory guide. Transl Pediatr 2021;10(4):1201-30.** PMID 34012862
12: Bley A, Denecke J, Kohlschutter A, et al. The natural history of Canavan disease: 23 new cases and comparison with patients from literature. Orphanet J Rare Dis 2021;16(1):227.** PMID 34011350
13: Cakar NE, Aksu Uzunhan T. A case of juvenile Canavan disease with distinct pons involvement. Brain Dev 2020;42(2):222-5. PMID 31839386
14: Canavan MM. Schilder’s encephalitis periaxialis diffusa: report of a case in a child aged sixteen and one-half months. Archives of Neurology & Psychiatry 1931;25(2):299-308.
15: Chao J, Feng L, Ye P, et al. Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene. iScience 2022;25(6):104391. PMID 35637731
16: Dembic M, Andersen HS, Bastin J, et al. Next generation sequencing of RNA reveals novel targets of resveratrol with possible implications for Canavan disease. Mol Genet Metab 2019;126(1):64-76. PMID 30446350
17: Dewulf JP, Wiame E, Dorboz I, et al. SLC13A3 variants cause acute reversible leukoencephalopathy and α-ketoglutarate accumulation. Ann Neurol 2019;85(3):385-95. PMID 30635937
18: Drera B, Poggiani C. Brain ultrasound in Canavan disease. J Ultrasound 2014;17(3):215-7. PMID 25177395
19: Elpeleg ON, Shaag A, Anikster Y, Jakobs C. Prenatal detection of Canavan disease (aspartoacylase deficiency) by DNA analysis. J Inherit Metab Dis 1994;17(6):664-6. PMID 7707689
20: Fares F, Baderneh K, Abosaleh M, Harari-Shaham A, Diukman R, David M. Carrier frequency of autosomal-recessive disorders in the Ashkenazi Jewish population: should the rationale for mutation choice for screening be reevaluated. Prenat Diagn 2008;28(3):236-41. PMID 18264947
21: Feigenbaum A, Moore R, Clarke J, Hewson S, Chitayat S, Ray PN, Stockley TL. Canavan disease: carrier-frequency determination in the Ashkenazi Jewish population and development of a novel molecular diagnostic assay. Am J Med Genet A 2004;124A(2):142-7. PMID 14699612
22: Feng L, Chao J, Tian E, et al. Cell-based therapy for Canavan disease using human iPSC-derived NPCs and OPCs. Adv Sci (Weinh) 2020;7(23):2002155. PMID 33304759
23: Francis JS, Markov V, Leone P. Dietary triheptanoin rescues oligodendrocyte loss, dysmyelination and motor function in the nur7 mouse model of Canavan disease. J Inherit Metab Dis 2014;37(3):369-81. PMID 24288037
24: Francis JS, Markov V, Wojtas ID, et al. Preclinical biodistribution, tropism, and efficacy of oligotropic AAV/Olig001 in a mouse model of congenital white matter disease. Mol Ther Methods Clin Dev 2021;20:520-34. PMID 33614826
25: Fröhlich D, Kalotay E, von Jonquieres G, et al. Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice. Front Mol Neurosci 2022;15:1061257. PMID 36568275
26: Gregg AR, Aarabi M, Klugman S, et al. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 2021;23(10):1793-806. PMID 34285390
27: Grodd W, Krageloh-Mann I, Peterson D, Trefz FK, Harzer K. In vivo assessment of N-acetylaspartate in brain in spongy degeneration (Canavan disease) by proton spectroscopy. Lancet 1990;336:437-8. PMID 1974962
28: Hoshino H, Kubota M. Canavan disease: clinical features and recent advances in research. Pediatr Int 2014;56(4):477-83. PMID 24977939
29: Hull V, Wang Y, Burns T, et al. Antisense oligonucleotide reverses leukodystrophy in Canavan disease mice. Ann Neurol 2020;87(3):480-5. PMID 31925837
30: Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002;13:1391-412. PMID 12162821
31: Janson CG, Kolodny EH, Zeng BJ, et al. Mild-onset presentation of Canavan’s disease associated with novel G212A point mutation in aspartoacylase gene. Ann Neurol 2006;59(2):428-31. PMID 16437572
32: Karimzadeh P, Jafari N, Nejad Biglari H, et al. The clinical features and diagnosis of Canavan's disease: a case series of Iranian patients. Iran J Child Neurol 2014;8(4):66-71. PMID 25657773
33: Kaul R, Gao GP, Balamurugan K, Matalon R. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. Nat Genet 1993;5:118-23. PMID 8252036
34: Kaul R, Gao GP, Matalon R, et al. Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 1996;59:95-102. PMID 8659549
35: Keller SR, Mallack EJ, Rubin JP, et al. Practical approaches and knowledge gaps in the care for children with leukodystrophies. J Child Neurol 2021;36(1):65-78.** PMID 32875938
36: Kolodziejczyk K, Hamilton NB, Wade A, Káradóttir R, Attwell D. The effect of N-acetyl-aspartyl-glutamate and N-acetyl-aspartate on white matter oligodendrocytes. Brain 2009;132(Pt 6):1496-508. PMID 19383832
37: Kotambail A, Selvam P, Muthusamy K, et al. Clustering of juvenile Canavan disease in an Indian community due to population bottleneck and isolation: genomic signatures of a founder event. Eur J Hum Genet 2023;31(1):73-80. PMID 36202930
38: Leone P, Janson CG, Bilaniuk L, et al. Aspartoacylase gene transfer to the mammalian central nervous system with therapeutic implications for Canavan disease. Ann Neurol 2000;48:27-38. PMID 10894213
39: Leone P, Shera D, McPhee SW, et al. Long-term follow-up after gene therapy for canavan disease. Sci Transl Med 2012;4(165):165ra163. PMID 23253610
40: Li M. Enzyme replacement therapy: a review and its role in treating lysosomal storage diseases. Pediatr Ann 2018;47(5):e191-7. PMID 29750286
41: Lotun A, Gessler DJ, Gao G. Canavan disease as a model for gene therapy-mediated myelin repair. Front Cell Neurosci 2021;15:661928.** PMID 33967698
42: Matalon R. Canavan disease: diagnosis and molecular analysis. Genet Test 1997;1:21-5. PMID 10464621
43: Matalon R, Delgado L, Michals-Matalon K, et al. Canavan disease. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle, 2022. PMID 20301412
44: Matalon R, Kaul R, Michals K. Canavan disease: biochemical and molecular studies. J Inherit Metab Dis 1993;16:744-52. PMID 8412017
45: Matalon R, Michals-Matalon K. Molecular basis of Canavan disease. Eur J Paediatr Neurol 1998;2:69-76. PMID 10724099
46: Matalon R, Michals K, Sebesta D, Deanching M, Gashkoff P, Casanova J. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. Am J Med Genet 1988;29(2):463-71. PMID 3354621
47: Matalon RM, Michals-Matalon K. Spongy degeneration of the brain, Canavan disease: biochemical and molecular findings. Front Biosci 2000;5:D307-11. PMID 10704428
48: Mendes MI, Smith DE, Pop A, et al. Clinically distinct phenotypes of Canavan disease correlate with residual aspartoacylase enzyme activity. Hum Mutat 2017;38(5):524-531. PMID 28101991
49: Nesuta O, Thomas AG, Alt J, et al. High throughput screening cascade to identify human aspartate N-acetyltransferase (ANAT) inhibitors for Canavan disease. ACS Chem Neurosci 2021;12(18):3445-55. PMID 34477360
50: Pederzolli CD, Rockenbach FJ, Zanin FR, et al. Intracerebroventricular administration of N-acetylasparticacid impairs antioxidant defenses and promotes protein oxidation in cerebral cortex of rats. Metab Brain Dis 2009;24:283-98. PMID 19294497
51: Pederzolli CD, Rosa AP, de Oliveira AS, et al. Neuroprotective role of lipoic acid against acute toxicity of N-acetylaspartic acid. Mol Cell Biochem 2010;344(1-2):231-9. PMID 20686917
52: Pleasure D, Guo F, Chechneva O, et al. Pathophysiology and treatment of Canavan disease. Neurochem Res 2020;45(3):561-5.** PMID 30535831
53: Poddar NK, Zano S, Natarajan R, Yamamoto B, Viola RE. Enhanced brain distribution of modified aspartoacylase. Mol Genet Metab 2014;113(3):219-24. PMID 25066302
54: Prokesch A, Pelzmann HJ, Pessentheiner AR, et al. N-acetylaspartate catabolism determines cytosolic acetyl-CoA levels and histone acetylation in brown adipocytes. Sci Rep 2016;6:23723. PMID 27045997
55: Reddy N, Calloni SF, Vernon HJ, Boltshauser E, Huisman T, Soares BP. Neuroimaging findings of organic acidemias and aminoacidopathies. Radiographics 2018;38(3):912-31. PMID 29757724
56: Rossler L, Lemburg S, Weitkämper A, et al. Canavan's spongiform leukodystrophy (Aspartoacylase deficiency) with emphasis on sonographic features in infancy: description of a case report and review of the literature. J Ultrasound 2023;26(4):757-64. PMID 35187608
57: Rushton AR, Shaywitz BA, Duncan CC, Geehr RB, Manuelidis EE. Computerized tomography in the diagnosis of Canavan's disease. Ann Neurol 1981;10:57-60. PMID 7271233
58: Segel R, Anikster Y, Zevin S. et al. A safety trial of high dose glyceryl triacetate for Canavan Disease. Mol Genet Metab 2011;103(3):203-6. PMID 21474353
59: Sreenivasan P, Purushothaman KK. Radiological clue to diagnosis of Canavan disease. Indian J Pediatr 2013;80(1):75-7. PMID 22660905
60: Surendran S. Upregulation of N-acetylaspartic acid alters inflammation, transcription and contractile associated protein levels in the stomach and smooth muscle contractility. Mol Biol Rep 2009;36(1):201-6. PMID 17943458
61: Surendran S. Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease. Med Hypotheses 2010;75(6):533-4. PMID 20673702
62: Surendran S, Bamforth FJ, Chan A, Tyring SK, Goodman SI, Matalon R. Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem. J Child Neurol 2003;18(11):809-12. PMID 14696913
63: Tacke U, Olbrich H, Sass JO, et al. Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease. Neuropediatrics 2005;36(4):252-5.** PMID 16138249
64: Taylor DL, Davies SE, Obrenovitch TP, et al. Investigation into the role of N-acetylaspartate in cerebral osmoregulation. J Neurochem 1995;65(1):275-81. PMID 7790871
65: van Bogaert L, Bertrand I. Sur une idiotie familiale avec degerescence sponglieuse de neuraxe (note preliminaire). Acta Neurol Belg 1949;49:572-87.
66: Wang Y, Hull V, Sternbach S, et al. Ablating the transporter sodium-dependent dicarboxylate transporter 3 prevents leukodystrophy in Canavan disease mice. Ann Neurol 2021;90(5):845-50. PMID 34498299
67: Wei H, Moffett JR, Amanat M, et al. The pathogenesis of and pharmacological treatment for Canavan disease. Drug Discov Today 2022;27(9):2467-83. PMID 35636725
68: Wittsack HJ, Kugel H, Roth B, Heindel W. Quantitative measurements with localized 1H MR spectroscopy in children with Canavan’s disease. J Magn Reson Imaging 1996;6:889-93. PMID 8956134
69: Yalcinkaya C, Benbir G, Salomons GS, et al. Atypical MRI findings in Canavan disease: a patient with a mild course. Neuropediatrics 2005;36(5):336-9. PMID 16217711
70: Yaron Y, Schwartz T, Mey-Raz N, Amit A, Lessing JB, Malcov M. Preimplantation genetic diagnosis of Canavan disease. Fetal Diagn Ther 2005;20:465-8. PMID 16113575
71: Zano S, Malik R, Szucs S, Matalon R, Viola RE. Modification of aspartoacylase for potential use in enzyme replacement therapy for the treatment of Canavan disease. Mol Genet Metab 2011;102:176-80. PMID 21095151
72: Zano S, Wijayasinghe YS, Malik R, Smith J, Viola RE. Relationship between enzyme properties and disease progression in Canavan disease. J Inherit Metab Dis 2013;36(1):159-160. PMID 22850825

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Authors

Alex Sunshine MD PhD

Dr. Sunshine of Nationwide Children's Hospital has no relevant financial relationships to disclose.
See Profile
Margie A Ream MD PhD

Dr. Ream of Ohio State University College of Medicine received consulting fees from Ionis Pharmaceuticals, INC.
See Profile

Editor

Erika Fullwood Augustine MD MS

Dr. Augustine of Kennedy Krieger Institute, Johns Hopkins University, and University of Rochester Medical Center received a clinical trial agreement as Central Rater from Neurogene Inc, and an honorarium as a member of the Data Safety and Monitory Board for PTC Therapeutics.
See Profile

Former Authors

Kimberlee Michals-Matalon PhD
Gita Masand PhD
Kacey Hart BS
Reuben Matalon MD PhD
Lisvania M Delgado-Pena MS2
Brianna M Young MS2
Dena Rae Matalon MD
Raphael Schiffmann MD

Patient Profile

Age range of presentation: 0 month to 5 years
Sex preponderance: male=female
Heredity: heredity may be a factor

heredity typical

autosomal recessive
Population groups selectively affected: Ashkenazi Jews
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Leukodystrophy: 330.0
ICD-10: Other sphingolipidosis: E75.2
OMIM: Canavan disease: #271900

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Canavan disease

Associated Disorders

Macrocephaly

Differential Diagnosis

Alexander disease
Tay-Sachs disease
megalencephalic leukoencephalopathy with subcortical cysts
autosomal dominant megalencephaly
Pelizaeus-Merzbacher disease
- viral infections
- mitochondrial diseases
- metabolic diseases
- homocystinuria

Also Relevant

Gene therapy of neurogenetic disorders
Leukodystrophies
Megalencephaly
Molecular diagnosis of neurogenetic disorders
White matter abnormalities in the brain

Canavan disease

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Confusing conditions

Associated or underlying disorders

Diagnostic workup

Management

Outcomes

Special considerations

Pregnancy

Anesthesia

References

Contributors

Authors

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Carnitine palmitoyltransferase II deficiency

Pyruvate carboxylase deficiency

Pelizaeus-Merzbacher disease

Vanishing white matter disease

Wilson disease

Aromatic L-amino acid decarboxylase deficiency

White matter abnormalities in the brain

Hypermethioninemia

This is an article preview.
Start a Free Account
to access the full version.